financetom
Business
financetom
/
Business
/
Stock 360: What dragged Larsen & Toubro by 5% today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stock 360: What dragged Larsen & Toubro by 5% today
Oct 29, 2020 8:06 AM

Larsen & Toubro (L&T), was down 5 percent on October 29, which has negated gains for the month. It has been an underperformer and this year L&T is down 28 percent and is down 38 percent from its 52 week high.

The stock's decline has been attributed to the lower interim dividend payout, which has led to concerns about its capital allocation policy as well. Its order book was below expectation and the stock had simply run-up because of expectation of very good dividend and the MSCI factor.

Here's a look at what dragged Larsen & Toubro in this special edition of Stock 360.

Watch the video for more.

(Edited by : Jerome Anthony)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Macy's Lowers Full-Year Sales Guidance Following Mixed Second-Quarter Results
Macy's Lowers Full-Year Sales Guidance Following Mixed Second-Quarter Results
Aug 21, 2024
10:21 AM EDT, 08/21/2024 (MT Newswires) -- Macy's (M) trimmed its full-year sales outlook on Wednesday amid an uncertain discretionary consumer market, as the department store operator's fiscal second-quarter topline declined on a yearly basis. Sales are now set to come in between $22.1 billion and $22.4 billion during the current fiscal year, compared with the company's prior projection of...
Sesame to Offer Novo Nordisk's Wegovy 'With No Retail Markup'
Sesame to Offer Novo Nordisk's Wegovy 'With No Retail Markup'
Aug 21, 2024
10:34 AM EDT, 08/21/2024 (MT Newswires) -- Healthcare marketplace Sesame said Wednesday that it will offer compounded versions of Novo Nordisk's ( NVO ) weight-loss drug Wegovy to qualified customers for $249 per month as part of its new weight-loss program in the US. Compounded semaglutide, the active ingredient in Wegovy, will be available to eligible customers with no retail...
-- ATS Brief: Closing $400 Million Senior Notes Offering
-- ATS Brief: Closing $400 Million Senior Notes Offering
Aug 21, 2024
09:59 AM EDT, 08/21/2024 (MT Newswires) -- Price: 37.38, Change: +0.25, Percent Change: +0.67 ...
Lexaria Bioscience Reports Blood Sugar Reductions in Ongoing Diabetes Study; Shares Fall
Lexaria Bioscience Reports Blood Sugar Reductions in Ongoing Diabetes Study; Shares Fall
Aug 21, 2024
10:34 AM EDT, 08/21/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) shares fell 2.7% in early trading Wednesday after the company reported blood sugar reductions of up to 2.50% in its ongoing animal study on GLP-1 diabetes treatments. At 56 days, DehydraTECH-liraglutide and two DehydraTECH-CBD formulations showed the highest blood sugar reductions of 2.50%, 1.90%, and 1.53%, respectively, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved